Algeria - Women's share of population ages 15+ living with HIV (%)

Women's share of population ages 15+ living with HIV (%) in Algeria was 45.60 as of 2020. Its highest value over the past 30 years was 45.60 in 2020, while its lowest value was 43.50 in 2008.

Definition: Prevalence of HIV is the percentage of people who are infected with HIV. Female rate is as a percentage of the total population ages 15+ who are living with HIV.

Source: UNAIDS estimates.

See also:

Year Value
1990 43.90
1991 44.30
1992 44.50
1993 44.70
1994 44.80
1995 44.90
1996 45.00
1997 45.00
1998 45.00
1999 44.60
2000 44.30
2001 44.20
2002 44.20
2003 44.20
2004 44.10
2005 43.90
2006 43.70
2007 43.60
2008 43.50
2009 43.50
2010 43.80
2011 44.20
2012 44.50
2013 44.80
2014 45.00
2015 45.20
2016 45.30
2017 45.40
2018 45.50
2019 45.50
2020 45.60

Limitations and Exceptions: The limited availability of data on health status is a major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or report information.

Statistical Concept and Methodology: HIV prevalence rates reflect the rate of HIV infection in each country's population. Low national prevalence rates can be misleading, however. They often disguise epidemics that are initially concentrated in certain localities or population groups and threaten to spill over into the wider population. In many developing countries most new infections occur in young adults, with young women especially vulnerable. Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries have resulted in improved estimates of HIV and AIDS. The models, which are routinely updated, track the course of HIV epidemics and their impact, making full use of information in HIV prevalence trends from surveillance data as well as survey data. The models take into account reduced infectivity among people receiving antiretroviral therapy (which is having a larger impact on HIV prevalence and allowing HIV-positive people to live longer) and allow for changes in urbanization over time in generalized epidemics. The estimates include plausibility bounds, which reflect the certainty associated with each of the estimates.

Aggregation method: Weighted average

Periodicity: Annual

Classification

Topic: Health Indicators

Sub-Topic: Risk factors